Lataa...
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model
The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by...
Tallennettuna:
Päätekijät: | , , , , , , , , , , |
---|---|
Aineistotyyppi: | Artigo |
Kieli: | Inglês |
Julkaistu: |
American Society for Clinical Investigation
2008
|
Aiheet: | |
Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2518074/ https://ncbi.nlm.nih.gov/pubmed/18725989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI34764 |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|